EAU 2014 - Poster: A phase 2 trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC)

STOCKHOLM, SWEDEN (UroToday.com) - Presented by D Petrylak,¹ D Smith,² L Appleman,³ M Fleming,⁴ A Hussain,⁵ R Dreicer,⁶ AO Sartor,⁷ N Shore,⁸ NJ Vogelzang,⁹ H Youssoufian,¹⁰ VA DiPippo,¹⁰ N Stambler,¹⁰ K Huang,¹⁰ RJ Israel¹⁰ at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

¹Yale University, New Haven, CT; ²University of Michigan, Ann Arbor, MI; ³University of Pittsburgh, Pittsburgh, PA; ⁴Virginia Oncology Associates, Norfolk, VA; ⁵University of Maryland, Baltimore, MD; ⁶Cleveland Clinic, Cleveland, OH; ⁷Tulane University, New Orleans, LA; ⁸Carolina Urologic Research Center, Myrtle Beach, SC; ⁹Comprehensive Cancer Centers of Nevada, Las Vegas, NV; ¹⁰Progenics Pharmaceuticals, Inc., Tarrytown, NY

Click HERE to listen to Daniel P. Petrylak, MD discuss the key points from this poster